Combination contraceptives: effects on weight
MF Gallo, LM Lopez, DA Grimes… - Cochrane Database …, 2014 - cochranelibrary.com
Background Weight gain is often considered a side effect of combination hormonal
contraceptives, and many women and clinicians believe that an association exists. Concern …
contraceptives, and many women and clinicians believe that an association exists. Concern …
New and emerging contraceptives: a state-of-the-art review
L Bahamondes, MV Bahamondes - International journal of …, 2014 - Taylor & Francis
Background The first hormonal contraceptive was introduced onto the market in several
countries 50 years ago; however, the portfolio of contraceptive methods remains restricted …
countries 50 years ago; however, the portfolio of contraceptive methods remains restricted …
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol
F Roumen, D Apter, TMT Mulders… - Human …, 2001 - academic.oup.com
A novel contraceptive vaginal ring releasing etonogestrel 120 μg and ethinyl oestradiol 15
μg daily over a period of 3 weeks was tested. Each ring was used for one cycle, comprising …
μg daily over a period of 3 weeks was tested. Each ring was used for one cycle, comprising …
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl …
HJ Ahrendt, D Makalová, S Parke, U Mellinger… - Contraception, 2009 - Elsevier
BACKGROUND: This study compared the bleeding pattern, cycle control and safety of an
oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered …
oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered …
Effects of oral contraceptives on body composition and physical performance in female athletes
A Rickenlund, K Carlstrom, B Ekblom… - The Journal of …, 2004 - academic.oup.com
Menstrual disturbances are common among female athletes, and oral contraceptives (OCs)
are often recommended as estrogen substitution. However, there is little information about …
are often recommended as estrogen substitution. However, there is little information about …
[HTML][HTML] Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus …
C Klipping, I Duijkers, S Parke, U Mellinger, M Serrani… - Drugs in R & D, 2011 - Springer
Background: A novel estradiol-based combined oral contraceptive (COC) is currently
available in many countries worldwide, including Europe and the US. Based on previous …
available in many countries worldwide, including Europe and the US. Based on previous …
Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy …
S Kelly, E Davies, S Fearns, C McKinnon… - Clinical Drug …, 2010 - Springer
Background: The combined oral contraceptive Yasmin®(drospirenone 3 mg plus
ethinylestradiol 30 μg [DRSP 3 mg/EE 30 μg]) has been shown to be a well tolerated and …
ethinylestradiol 30 μg [DRSP 3 mg/EE 30 μg]) has been shown to be a well tolerated and …
Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label …
J Endrikat, S Parke, D Trummer, W Schmidt, I Duijkers… - Contraception, 2008 - Elsevier
BACKGROUND: Attempts to improve the tolerability of combined oral contraceptives (COCs)
have included the substitution of ethinylestradiol (EE) with 17β-estradiol (E2). However, this …
have included the substitution of ethinylestradiol (EE) with 17β-estradiol (E2). However, this …
Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles …
R Yildizhan, B Yildizhan, E Adali, P Yoruk… - Archives of gynecology …, 2009 - Springer
Objective The aim of this study is to compare the effect of ethinyl estradiol 0.03
mg/gestodene 0.075 mg (EE/GSD) with ethinylestradiol 0.03 mg/drospirenone 3 mg …
mg/gestodene 0.075 mg (EE/GSD) with ethinylestradiol 0.03 mg/drospirenone 3 mg …
A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 …
J Endrikat, U Müller, B Düsterberg - Contraception, 1997 - Elsevier
The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …